Formation of 3-hydroxyglutaric acid in glutaric aciduria type I: in vitro participation of medium chain acyl-CoA dehydrogenase

Verena Peters1 | Marina Morath1 | Matthias Mack2 | Michael Liesert3 | Wolfgang Buckel3 | Georg F. Hoffmann1 | Jerry Vockley4 | Sandro Ghisla5 | Johannes Zschocke6

1Center für Paediatric and Adolescent Medicine, University of Heidelberg, Germany
2Institut für Technische Mikrobiologie, Hochschule Mannheim, Germany
3Laboratorium für Mikrobiologie, Fachbereich Biologie, Philipps-Universität Marburg, Germany
4Department of Pediatric and Human Genetics, Children’s Hospital of Pittsburgh and University of Pittsburgh, Pittsburgh, Pennsylvania
5Department of Biology, Section of Natural Sciences, Universität Konstanz, Germany
6Division of Human Genetics, Medical University Innsbruck, Austria

Correspondence
Verena Peters, University Children Hospital, University of Heidelberg, Im Neuenheimer Feld 669, D-69120 Heidelberg, Germany. Email: verena.peters@med.uni-heidelberg.de
Johannes Zschocke, Division of Human Genetics, Medical University Innsbruck, Peter-Mayr-Str. 1, 6020 Innsbruck, Austria. Email: johannes.zschocke@i-med.ac.at

Communicating Editor: Eva Morava

Funding information
Deutsche Forschungsgemeinschaft (DE), Grant/Award Number: ZS 17/4

Abstract
3-Hydroxyglutaric acid (3-OH-GA) in urine has been identified as the most reliable diagnostic marker for glutaric aciduria type I (GA I). We showed that hydration of glutaryl-CoA to 3-hydroxyglutaryl-CoA, which is subsequently hydrolyzed to 3-OH-GA, is efficiently catalyzed by 3-methylglutaconyl-CoA hydratase (3-MGH). We have now investigated whether mitochondrial acyl-CoA-dehydrogenases can convert glutaryl-CoA to glutaconyl-CoA. Short-chain acyl-CoA dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD) accepted glutaryl-CoA as a substrate. The highest $k_{cat}$ of glutaryl-CoA was found for MCAD (0.12 ± 0.01 second$^{-1}$) and was about 26-fold and 52-fold higher than those of LCAD and SCAD, respectively. The turnover of MCAD for glutaryl-CoA was about 1.5% of that of its natural substrate octanoyl-CoA. Despite high $K_m$ (above 600 μM) and low turnover rate, the oxidation of glutaryl-CoA by MCAD in combination with 3-MGH could explain the urinary concentration of 3-OH-GA in GA I patients.

KEYWORDS
3-hydroxyglutaric acid, acyl-CoA dehydrogenase, glutaryl-CoA, glutaric aciduria type I, glutaryl-CoA

1 | INTRODUCTION

Glutaric aciduria type I (GA I) is an inborn error of metabolism that results from deficiency of glutaryl-CoA dehydrogenase (GCDH), which catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA.1,2 Two biochemically defined subgroups of patients have been described based on urinary metabolite excretion of glutaric acid (GA). Most patients excrete large amounts (high excretors) of GA with urinary concentrations between 850 and 1700 mmol/mol creatinine.2,3 However, in some GA I patients (low excretors), the urinary concentration of this compound is within the normal range of up to 4 mmol/mol creatinine.5 Indeed, there are some GA I patients who were identified solely by increased urinary metabolism of glutaric acid (GA).
concentrations of 3-hydroxyglutaric acid (3-OH-GA), which is found in both, “high excretor” and “low excretor” patients.5–7 Increased levels of 3-OH-GA have also been found in patients with short-chain 3-hydroxyacyl CoA dehydrogenase (SCAD) deficiency,8 in patients with disorders of long-chain fatty acid oxidation and mitochondrial disorders,9 and in ketotic patients.10 It has been suggested that 3-OH-glutaryl-CoA may be produced in constant but limited amounts from accumulating glutaryl-CoA via glutaconyl-CoA in a two-step process mediated by mitochondrial β-oxidation enzymes. We previously showed that hydration of glutaconyl-CoA to 3-OH-glutaryl-CoA is efficiently catalyzed by 3-methylglutaconyl-CoA hydratase (3-MGH).11 We now investigated whether mitochondrial acyl-CoA dehydrogenases (ACADs) can convert glutaryl-CoA to glutaconyl-CoA, and thus, in combined action with 3-MGH, could explain the formation of 3-OH-GA in GA I patients.

2 MATERIALS AND METHODS

Recombinant human medium-chain acyl-CoA dehydrogenase (MCAD) was expressed and purified as described before,12,13 recombinant human long-chain acyl CoA dehydrogenase (LCAD) as described by Eder et al. 1997 and short-chain acyl CoA dehydrogenase (SCAD) as described in reference 14 butyryl-CoA, propionyl-CoA, hexanoyl-CoA, octanoyl-CoA, phenylpropionyl-CoA, and palmitoyl-CoA, glutaryl-CoA were obtained from Sigma-Aldrich (St. Louis, Missouri).

The activity of recombinant human acyl-CoA dehydrogenases13 was measured at different substrate concentrations in Tris buffer with an assay using ferricenium hexafluorophosphate as an electron acceptor.15 Enzyme activity was additionally confirmed by identification of the product glutaconyl-CoA by HPLC and analyzing it by mass spectrometry.11 The kinetic constants (K_m and V_max) were estimated by computer-fitting of the data (n = 4) using an algorithm based on the Michaelis-Menten equation. The turnover number (k_cat) was calculated using the molecular mass of the acyl-CoA dehydrogenases (43 kDa).16,17 In addition to glutaryl-CoA, the activities of acyl-CoA dehydrogenases toward their (optimal) substrates were determined as a control. The pH dependence of the activity toward the different substrates was measured in the range of pH 7.0-8.5 in Tris buffer adjusted to the desired pH value with KOH or HCl.

3 RESULTS

All three ACADs were able to catalyze the dehydrogenation of glutaryl-CoA to glutaconyl-CoA (Table 1). The production of glutaconyl-CoA was demonstrated by the ferricenium assay and by identification of the product by HPLC followed by mass spectrometry. At pH 7.5, MCAD exhibited the highest k_cat of 0.12 second⁻¹, although about 70 times lower than with the natural substrate octanoyl-CoA. SCAD and LCAD were much less active for the substrate glutaryl-CoA with k_cat values of 0.0023 and 0.0045 second⁻¹, respectively. Interestingly, the K_m values for glutaryl-CoA were about equal with each enzyme (600-900 μM), indicating that only the CoA moiety is responsible for binding to the enzyme, whereas the hydrophilic glutaryl-CoA moiety does not interact well with the hydrophobic binding pockets. With increasing pH, the specific activities of all ACADs with their “natural” substrates increased for all three enzymes (Figure 1, top panel). In contrast, the activity of MCAD with glutaryl-CoA at high concentration (1.2 mM) exhibited an “opposite” behavior, that is, it decreased with pH. SCAD and LCAD, on the other hand, behaved much as with their normal substrates, although the increase in activity with increasing pH was comparatively small (Figure 1, bottom panel). At pH >8.5, the difference in activities between MCAD and SCAD or LCAD per enzyme quantity was only about 5-fold. Noteworthy is also that at lower glutaryl-CoA concentration (<600 μM) the activities were substantially reduced for all three enzymes at all pH values.

Table 1 Kinetic parameters for MCAD, SCAD, and LCAD (kinetic parameters for the substrate glutaryl-CoA are given in bold)

| Enzyme | Substrate       | K_m (μM) | k_cat (s⁻¹)         | k_cat/K_m (pM⁻¹ second⁻¹) |
|--------|-----------------|----------|---------------------|----------------------------|
| SCAD   | Glutaryl-CoA    | 850 ± 98 | 0.0023 ± 0.0001     | 2.7                        |
|        | Hexanoyl-CoA    | 430 ± 29 | 0.014 ± 0.006       | 33                         |
| MCAD   | Octanoyl-CoA    | 6.0 ± 0.3| 8.2 ± 0.4           | 1 360 000                  |
|        | Glutaryl-CoA    | 660 ± 42 | 0.12 ± 0.01         | 180                        |
| LCAD   | Palmitoyl-CoA   | 63 ± 4   | 0.143 ± 0.023       | 2300                       |
|        | Glutaryl-CoA    | 650 ± 45 | 0.0045 ± 0.0001     | 6.9                        |

Synopsis

3-OH-GA in GA I is most likely generated through MCAD-mediated dehydrogenation of accumulating glutaryl-CoA followed by 3-MGH-mediated hydration and spontaneous hydrolysis.
DISCUSSION

Kinetic data obtained with recombinant human MCAD, SCAD, and LCAD in the present study provide a rationale for previously unexplained biochemical findings in patients with classical and atypical forms of GA I. GA, the product of hydrolysis of glutaryl-CoA, is usually the dominating pathological metabolite in GA I but present in highly variable concentrations. In contrast, the formation of 3-hydroxyglutarate in GA I appears to be quite stable at approximately 0.1 mol per day and is independent from the urinary concentrations of GA (unpublished observation). Our present data indicate that the oxidation of glutaryl-CoA in GA I is most probable catalyzed by MCAD rather than by SCAD or LCAD, with high $K_m$ and low turnover rates, although we cannot exclude that other acyl-CoA dehydrogenases, like isovaleryl-CoA dehydrogenase, may also be involved in the oxidation of glutaryl-CoA and thus may contribute to the formation of 3-OH-GA. Future in vivo studies and/or tracer flux analyses taking into account the complete cell metabolism should be able to provide more details on metabolic rerouting in GCDH deficiency.

Acyl-CoA dehydrogenases belong to the family of homotetrameric flavoenzymes with subunit molecular masses of 40 to 50 kDa that mediate the $\alpha,\beta$-dehydrogenation of acyl-CoA thioesters to enoyl-CoA in the mitochondrial $\beta$-oxidation of fatty acids and are also involved in the degradation of leucine, isoleucine, valine, and lysine. As previously reported, the activities of ACADs are strongly pH dependent and dependent on the type of buffer used. Assuming a pH around 7.5 within the cell, the dehydrogenation of glutaryl-CoA by MCAD (and to a much lesser extent by SCAD and LCAD) is expected to occur at a low but constant rate at concentrations in the mM range. Such concentrations are thought to be reached in the mitochondria of all (classical and atypical) patients with GA I, including those with “mild” GA I and residual GCDH activity. Assuming that there is no “better” enzyme for this reaction, the first step in the short pathway to 3-OH-glutaryl-CoA biosynthesis would be rate limiting, and turnover is not significantly affected by changes in mitochondrial glutaryl-CoA concentrations from “very high” to “extremely high” in different variants of GA I. In “low excretor” patients with at least one hypomorphic $GCDH$ mutation and residual enzyme function, the intramitochondrial elevation of glutaryl-CoA is sufficient to lead to noticeable conversion into glutaconyl-CoA without noticeable production of free GA. 3-MGH efficiently converts glutaconyl-CoA to 3-OH-glutaryl-CoA with a $k_{cat}$ of 1.4 seconds$^{-1}$ in a reversible reaction. After hydrolysis, the products glutaconic and 3-hydroxyglutaric acid is excreted as free acid into the blood and finally into the urine (Figure 2).
The formation of 3-OH-GA in patients with SCAD or LCAD deficiency appears to be unrelated to the accumulation of glutaryl-CoA as a precursor of 3-OH-glutaryl-CoA. Molven et al. suggested that 3-OH-glutaryl-CoA may be hydrolyzed to 3-OH-GA when the conversion of 3-OH-glutaryl-CoA to 3-ketoglutararyl-CoA is blocked. The increased excretion of 3-OH-GA in ketotic patients was thought to be caused by increased protein catabolism and thus increased flux through the lysine degradative pathway.

There is no urinary excretion of 3-OH-GA in glutaric aciduria type II (GA II), the deficiency of the electron transferring flavoprotein (ETF), which mediates the electron transport from all mitochondrial acyl-CoA dehydrogenases (including SCAD, MCAD, and LCAD) to the respiratory chain. Instead, the excretion of 2-OH-GA is a useful marker for this disease.

In conclusion, we report that 3-OH-GA in GA I is most likely generated through MCAD-mediated dehydrogenation of accumulating glutaryl-CoA followed by 3-MGH-mediated hydration and spontaneous hydrolysis. Throughtput in this pathway appears to be not proportional to the amount of accumulating glutaryl-CoA, explaining a constant production of 3-OH-GA relatively independent of residual GCDH activity. GA production, in contrast, is much more dependent on residual GCDH activity, with high excretion only in severe enzyme deficiency. Thus, 3-OH-GA is the most sensitive metabolic indicator of impaired GCDH function.

ACKNOWLEDGMENTS

This study was supported by the Deutsche Forschungsgemeinschaft (ZS 17/4).

AUTHOR CONTRIBUTIONS

All authors contributed to this article. Verena Peters and Johannes Zschocke were involved in planning data evaluation and writing this article. Matthias Mack, Michael Liesert, Wolfgang Buckel, Jerry Vockley, and Sandro Ghisla were involved in the experiments. Marina Morath and Georg Hoffmann critically revised the manuscript. All authors reviewed the final manuscript and gave approval for submission.

COMPETING INTEREST STATEMENT

All authors declare that they have no conflict of interest.

ORCID

Verena Peters https://orcid.org/0000-0002-4649-0848
Johannes Zschocke https://orcid.org/0000-0002-0046-8274

REFERENCES

1. Boy N, Mülhäusen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017;40:75-101.
2. Hedlund GL, Longo N, Pasquali M. Glutaric acidemia type I. Am J Med Genet C Semin Med Genet. 2006;15:86-94.
3. Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC. Glutaric aciduria; a "new" disorder of amino acid metabolism. Biochem Med. 1975;12:12-21.
4. Hoffmann GF, Zschocke J. Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis. 1999;22:381-391.
5. Busquets C, Merinero B, Christensen E, et al. Glutaryl-CoA dehydrogenase deficiency in Spain: evidence of two groups of patients, genetically, and biochemically distinct. Pediatr Res. 2000;48:315-322.
6. Christensen E, Ribes A, Merinero B, Zschocke J. Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27:861-868.
7. Nyhan WL, Zschocke J, Hoffmann G, Stein DE, Bao L, Goodman S. Glutaryl-CoA dehydrogenase deficiency presenting as 3-hydroxyglutaric aciduria. Mol Genet Metab. 1999;66:199-204.
8. Molven A, Matre GE, Duran M, et al. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes. 2004;53:221-227.
9. Baric I, Zschocke J, Christensen E. Diagnosis and management of glutaric aciduria type I. J Inherit Metab Dis. 1998;21:326-340.
10. Pitt J, Carpenter K, Wilcken B, Boneh A. 3-Hydroxyglutarate excretion is increased in ketotic patients: implications for glutaryl-CoA dehydrogenase deficiency testing. J Inherit Metab Dis. 2002;25:83-88.
11. Mack M, Schniegler-Mattux U, Peters V, et al. Biochemical characterization of human 3-methylglutaconyl-CoA hydratase and its role in leucine metabolism. FEBS J. 2006;273:2012-2022.
12. Battaile K, Mohsen A-W, Vockley J. Functional role of the active site glutamate-368 in rat short chain acyl-CoA dehydrogenase. Biochemistry. 1996;35:15356-15363.
13. Bross P, Andresen BS, Winter V, et al. Co-overexpression of bacterial GroESL chaperonins partly overcomes non-productive folding and tetramer assembly of E. coli-expressed human medium-chain acyl-CoA dehydrogenase (MCAD) carrying the prevalent disease-causing K304E mutation. Biochim Biophys Acta. 1993;1182:264-274.
14. Nguyen TV, Riggins C, Babovic-Vuksanovic D, et al. Purification and characterization of two polymorphic variants of short chain acyl-CoA dehydrogenase reveal reduction of catalytic activity and stability of the Gly185Ser enzyme. Biochemistry. 2002;41:11126-11133.
15. Lehman TC, Hale DE, Bhala A, Thorpe C. An acyl-coenzyme A dehydrogenase assay utilizing the ferricenium ion. Anal Biochem. 1990;186:280-284.
16. Finocchiaro G, Ito M, Tanaka K. Purification and properties of short chain acyl-CoA, medium chain acyl-CoA, and isovaleryl-CoA dehydrogenases from human liver. *J Biol Chem*. 1987;262:7982-7989.

17. Ikeda Y, Okamura-Ikeda K, Tanaka K. Purification and characterization of short-chain, medium chain, and long-chain acyl-CoA dehydrogenases from rat liver mitochondria. Isolation of the holo- and apoenzymes and conversion of the apoenzyme to the holoenzyme. *J Biol Chem*. 1985;260:1311-1325.

18. Ghisla S, Thorpe C. Acyl-CoA dehydrogenases. A mechanistic overview. *Eur J Biochem*. 2004;271:494-508.

19. Beckmann JD, Frerman FE. The effects of pH, ionic strength, and chemical modifications on the reaction of electron transfer flavoprotein with an acyl coenzyme A dehydrogenase. *J Biol Chem*. 1983;258:7563-7569.

20. Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. *Mol Genet Metab*. 2008;93:36-39.